hydroxychloroquine and Cerebral Infarction, Middle Cerebral Artery
hydroxychloroquine has been researched along with Cerebral Infarction, Middle Cerebral Artery in 1 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
Research
Studies (1)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (100.00) | 2.80 |
Authors
Authors | Studies |
---|---|
Valderrama, EV | 1 |
Humbert, K | 1 |
Lord, A | 1 |
Frontera, J | 1 |
Yaghi, S | 1 |
Clinical Trials (1)
Trial Overview
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Long-term Neurocognitive and Psychiatric Consequences of COVID-19 in Patients Discharged From Critical Care Units. A Cohort Study of the Advance Interdisciplinary Rehabilitation Register (AIRR) Covid-19 Working Group.[NCT05019300] | 80 participants (Anticipated) | Observational | 2021-05-24 | Recruiting | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Reviews
1 review available for hydroxychloroquine and Cerebral Infarction, Middle Cerebral Artery
Article | Year |
---|---|
Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Ischemic Stroke.
Topics: Betacoronavirus; Carotid Artery, Internal; Carotid Stenosis; Cerebral Angiography; Clinical Laborato | 2020 |